摘要: |
目的:构建前列腺癌PSA特异性树突状细胞(PSADC)瘤苗,并观察其体外免疫活性,为后续研究奠定基础。方法:分离骨髓前体细胞,大量制备骨髓DCs(bone marrow derived DC,BMDC);分别以PSA、癌细胞裂解产物(lysate,Lys)、无关蛋白卵清蛋白(Ova)冲击DC制备PSADC、LysDC、OvaDC瘤苗。ELISA法检测PSADC瘤苗培养上清中细胞因子(IL12 p70和IL1β)水平的变化;观察PSADC瘤苗刺激抗原特异性T细胞增殖活性和诱导抗原特异性CTL杀伤活性,并与LysDC、OvaDC瘤苗及未加入抗原冲击的DC(NonDC)组作比较。结果:成功获得成熟DC,纯度可以达到>95%。ELISA法检测结果表明,PSADC、LysDC和OvaDC组培养上清中IL12 p70和IL1β水平均较NonDC组明显升高(P<0.05)。混合淋巴细胞培养(MLR)显示:PSADC、LysDC组DCs刺激CD4+T细胞增殖的能力明显优于OvaDC、NonDC组(P<0.01);PSADC、LysDC组培养上清中IL2、IFNγ水平明显高于后两者(P<0.01),而IL10和IL4水平下调(P<0.05)。PSADC、LysDC组可产生针对PSA和肿瘤裂解物的DTH反应,而对无关抗原无效(P<0.05)。与OVADC、NonDC组相比,LysDC、PSADC组体外诱导的CTL细胞对LNCaP细胞的杀伤活性较强 (P<0.05),且具有抗原特异性。结论:利用PSA蛋白冲击DC可成功制备PSA特异性DC瘤苗,该瘤苗体外具有较强的免疫活性,能有效杀伤LNCaP细胞。 |
关键词: 树突细胞 前列腺特异抗原 前列腺癌 癌症疫苗 细胞毒性T淋巴细胞 |
DOI:10.3724/SP.J.1008.2009.0265 |
投稿时间:2007-12-14修订日期:2008-09-16 |
基金项目:上海市科委基金(044119615). |
|
Construction of PSA specific dendritic cell vaccine and its in vitro immune activity |
XU Danfeng*, GAO Yi, LIU Yushan*, CUI Xingang, CHE Jianping, YIN Lei, XING Jizhang, YAO Yacheng, REN Jizhong, MIN Zhilian |
(Department of Urology, Urology Center of PLA, Changzheng Hospital, Second Military Medical University, Shanghai 200003, China) |
Abstract: |
Objective:To construct of PSAspecific dendritic cell (DC) vaccine and to observe its in vitro antitumour activity, so as to pave a way for future study. Methods: Bone marrow precursors were isolated and bone marrow derived DCs were prepared. Mature DCs were pulsed by PSA, Lysate of cancer cells, OVA and PBS to yield PSADC, Lys DC, OvaDC, and NonDC, respectively. After primed by antigen, the changes of IL12 p70 and IL1β in the supernatant of dendritic cells were assessed by ELISA. The antigenspecific proliferation and cytotoxicity activity of T cellprimed by PSApulsed DCs were observed and the results were compared with those by Lys, Ova and PBSpulsed DCs. Results: Mature DCs were successfully derived from bone marrow cells with a purity higher than 95%. ELISA assay showed PSADC, LysDC and OvaDC group secreted high levels of IL12 p70 and IL1β than NonDC group (P<0.05). In addition, PSADCs and LysDCs had significantly stronger ability to stimulate the proliferation of CD4+T cells in 3day classic mixed lymphocyte reaction (MLR) compared with OvaDCs and NonDCs (P<0.01). Higher levels of IFNγ and IL2 were detected in PSADCs and LysDCs groups compared with the other two groups (P<0.01), whereas the levels of IL10 and IL4 were lower than the other two groups (P<0.05). Moreover, PSADCs and Lys DCs enhanced DTH responses of C57BL/6 mice after antigen immunization; the third antigen and control did not show the enhancement effect (P<0.05). To observe the in vitro antiPSA CTL reactions induced by PSADCs and LysDCs, the LNCaP cell line (PSA specific) was used as syngeneic target and the E.G7 cell line (H2b) was used as Ovaspecific target cells. Compared with OvaDCs and NonDCs, CTL cells induced by PSADCs, LysDCs had significantly enhanced antigenspecific CTL activity to LNCaP cells (P<0.05).Conclusion: DCbased PSAepitope vaccine can be prepared by pulsing DCs with PSA protein; the prepared vaccine has strong in vitro immune activity and can kill LNCaP cells. |
Key words: dendritic cells prostate specific antigen prostatic neoplasms cancer vaccines cytotoxic T lymphocytes |